Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldenberg

Showing results (161-170 of 296) with videos related to

Pageof 30
Sort By:
Cancer Research|August 19, 2017
Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T CellsChien-Hsing Chang, Yang Wang, Rongxiu Li, et al.
Cancer|February 4, 2010
Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapyLudovic Ferrer, Françoise Kraeber-Bodéré, Caroline Bodet-Milin, et al.
JAMA Dermatology|August 19, 2014
Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgarisChristoph T Ellebrecht, Eun J Choi, David M Allman, et al.
Haematologica|August 24, 2014
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphomaThomas E Witzig, Michael B Tomblyn, Jamal G Misleh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
CD74: a new candidate target for the immunotherapy of B-cell neoplasmsRhona Stein, M Jules Mattes, Thomas M Cardillo, et al.
British Journal of Haematology|October 12, 2013
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myelomaJonathan L Kaufman, Ruben Niesvizky, Edward A Stadtmauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphomaRhona Stein, Zhengxing Qu, Susan Chen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 28, 2017
Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor ModelMarlène C H Hekman, Mark Rijpkema, Desirée L Bos, et al.
International Journal of Cancer|August 15, 2003
Experimental radioimmunotherapy of small peritoneal metastases of colorectal originManuel J Koppe, Annemieke C Soede, Wikke Pels, et al.
Arthritis Research & Therapy|November 6, 2010
Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosusCapucine Daridon, Daniela Blassfeld, Karin Reiter, et al.
Pageof 30

Showing results (161-170 of 296) with videos related to

Sort By:
Pageof 30
Cancer Research|August 19, 2017
Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T CellsChien-Hsing Chang, Yang Wang, Rongxiu Li, et al.
Cancer|February 4, 2010
Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapyLudovic Ferrer, Françoise Kraeber-Bodéré, Caroline Bodet-Milin, et al.
JAMA Dermatology|August 19, 2014
Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgarisChristoph T Ellebrecht, Eun J Choi, David M Allman, et al.
Haematologica|August 24, 2014
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphomaThomas E Witzig, Michael B Tomblyn, Jamal G Misleh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
CD74: a new candidate target for the immunotherapy of B-cell neoplasmsRhona Stein, M Jules Mattes, Thomas M Cardillo, et al.
British Journal of Haematology|October 12, 2013
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myelomaJonathan L Kaufman, Ruben Niesvizky, Edward A Stadtmauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphomaRhona Stein, Zhengxing Qu, Susan Chen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 28, 2017
Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor ModelMarlène C H Hekman, Mark Rijpkema, Desirée L Bos, et al.
International Journal of Cancer|August 15, 2003
Experimental radioimmunotherapy of small peritoneal metastases of colorectal originManuel J Koppe, Annemieke C Soede, Wikke Pels, et al.
Arthritis Research & Therapy|November 6, 2010
Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosusCapucine Daridon, Daniela Blassfeld, Karin Reiter, et al.
Pageof 30